Several San Diego life sciences companies raised money in the past few weeks, based on Form D notifications that companies are required to file with government regulators within 15 days after the first sale of securities in such offerings. The filings do not list the investors, however. Here’s a quick rundown of what I found:
—San Diego-based Biomatrica, which has developed technology that “shrink wraps” biological samples to protect them from degradation, has raised slightly more than $3 million, according to a recent regulatory filing. The company, which Luke profiled in 2009, plans to raise a total $3.3 million in equity and rights. Dow Jones VentureWire reports the company previously raised $1.2 million toward a $5 million equity round, with another $298,000 in rights and securities. The company’s past investors include In-Q-Tel, Mesa Verde Venture Partners, and existing angel investors.
—Celladon, a San Diego startup developing gene therapy treatments for heart attacks and other serious cardiovascular events, has landed $250,000 in debt and securities, according to a recent regulatory filing. The company, which raised $400,000 in July, has received close to $60 million from investors that include Enterprise Partners Venture Capital, Domain Associates, Johnson & Johnson Development Corp., Kleiner Perkins Caufield & Byers, and Venrock. Luke reported last year that a high dose of Celladon’s gene therapy offered a 50 percent lower risk of heart failure when compared with a placebo.
—San Diego’s Abrexa Pharmaceuticals raised $500,000 in a combination of debt, rights, and equity, according to a regulatory filing. Domain Associates’ partner Eckhard Weber is identified as both an executive and director of the startup, but Weber did not respond yesterday to an e-mail query about the company. It also is not listed as a portfolio company on Domain’s website.